Abstract

Mona Galatia74873*, RizkySyahriar Syoufana74874, Albertus Johan Edym74875 and Yuli Trisetiyono74876

Current infertility treatment practices are shifting from standardized to personalized Follicle Stimulating Hormone (FSH) dosing, with new FSH preparations incorporating individualized dosing in their clinical development. The commonly used regimens include recombinant FSH combined with human menopausal gonadotropin. This study aims to examine the effects of follitropin alpha and follitropin delta on ovarian stimulation, specifically focusing on embryo development and quality of In Vitro Fertilization (IVF) cycles.

This cross-sectional was held at Dr. Kariadi Central General Hospital from January 2022 to June 2024. All cycles involved controlled ovarian stimulation using recombinant FSH with either a Gonadotropin Releasing Hormone (GnRH) antagonist, long GnRH agonist or flare GnRH agonist protocols. This study includes patients undergoing IVF treatment at the fertility clinic who completed all necessary laboratory examinations.

In this study, a sample of 67 patients were consisted with 30 women in follitropin alpha and 37 women in follitropin delta who met the inclusion criteria and exclusion criteria. Patient demographics, treatment parameters, hormonal levels, pregnancy outcomes, oocyte retrieval and embryo transfer were studied. Most of the embryo transfers were fresh with mostly good quality.

Overall, follitropin delta provides superior outcomes in terms of higher oocyte retrieval rates, better pregnancy rates and more effective ovarian stimulation compared to some other FSH preparations. These advantages make it a valuable option for optimizing fertility treatments, though individual patient factors and treatment protocols should always be considered.